Should I buy or sell CollPlant Biotechnologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLGN shares. View CLGN analyst ratings or view top-rated stocks .

What is CollPlant Biotechnologies' stock price target for 2024?

2 brokerages have issued twelve-month target prices for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $22.75. On average, they expect the company's share price to reach $16.88 in the next year. This suggests a possible upside of 226.4% from the stock's current price. View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts .

How have CLGN shares performed in 2023?

CollPlant Biotechnologies' stock was trading at $8.35 at the beginning of 2023. Since then, CLGN shares have decreased by 38.1% and is now trading at $5.17. View the best growth stocks for 2023 here .

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,800 shares, a decrease of 15.6% from the October 31st total of 21,100 shares. Based on an average daily trading volume, of 14,600 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the shares of the company are sold short. View CollPlant Biotechnologies' Short Interest .

When is CollPlant Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our CLGN earnings forecast .

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.83. The business had revenue of $10.18 million for the quarter, compared to analysts' expectations of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the firm earned ($0.39) earnings per share.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA) , Boingo Wireless (WIFI) , Allena Pharmaceuticals (ALNA) , Advanced Micro Devices (AMD) , Energy Transfer (ET) , HTG Molecular Diagnostics (HTGM) , OPKO Health (OPK) , Ovid Therapeutics (OVID) and

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.31%), Villere ST Denis J & Co. LLC (2.71%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

CollPlant Biotechnologies Stock Price, News & Analysis (NASDAQ:CLGN)

$5.17

-0.18 (-3.36%)

(As of 12/8/2023 ET)

Compare

Today's Range: $5.15
▼
$5.45
50-Day Range: $4.98
▼
$6.64
52-Week Range: $4.70
▼
$13.97

Volume: 2,502 shs
Average Volume: N/A
Market Capitalization: $57.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.88

CollPlant Biotechnologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 226.4% Upside
$16.88 Price Target
Short Interest: Healthy
0.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.11 to ($0.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

558th out of 932 stocks

Surgical Appliances & Supplies Industry

15th out of 17 stocks

3.5

Analyst's Opinion

Consensus Rating
CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.88, CollPlant Biotechnologies has a forecasted upside of 226.4% from its current price of $5.17.
Amount of Analyst Coverage
CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.23% of the float of CollPlant Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CollPlant Biotechnologies has recently decreased by 15.64%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CollPlant Biotechnologies does not currently pay a dividend.
Dividend Growth
CollPlant Biotechnologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLGN.

N/A

News and Social Media Coverage

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.
Percentage Held by Institutions
Only 4.53% of the stock of CollPlant Biotechnologies is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CollPlant Biotechnologies are expected to decrease in the coming year, from $0.11 to ($0.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CollPlant Biotechnologies is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CollPlant Biotechnologies is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CollPlant Biotechnologies has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLGN Stock News Headlines

December 2, 2023 | benzinga.com

CollPlant Biotechnologies Stock (NASDAQ:CLGN), Analyst Ratings, Price Targets, Predictions

December 1, 2023 | finance.yahoo.com

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript

December 10, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 1, 2023 | americanbankingnews.com

CollPlant Biotechnologies (NASDAQ:CLGN) Receives "Buy" Rating from HC Wainwright

November 29, 2023 | benzinga.com

Recap: CollPlant Biotechnologies Q3 Earnings

November 29, 2023 | msn.com

CollPlant Biotechnologies Non-GAAP EPS of -$0.35

November 29, 2023 | finance.yahoo.com

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

November 9, 2023 | finance.yahoo.com

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

December 10, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 3, 2023 | finance.yahoo.com

Will CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?

November 1, 2023 | msn.com

CollPlant says patent granted in U.S. for photocurable dermal filler

November 1, 2023 | finance.yahoo.com

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

October 5, 2023 | finance.yahoo.com

Shareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years ago

September 21, 2023 | finance.yahoo.com

CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative

September 5, 2023 | finance.yahoo.com

CollPlant to Present at the H.C. Wainwright Annual Growth Conference

August 27, 2023 | finance.yahoo.com

Results: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts

August 26, 2023 | finance.yahoo.com

Investors Don't See Light At End Of CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Tunnel

August 25, 2023 | finance.yahoo.com

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Call Transcript

August 25, 2023 | markets.businessinsider.com

Collplant Holdings (CLGN) Gets a Buy from H.C. Wainwright

August 24, 2023 | seekingalpha.com

CollPlant Biotechnologies Non-GAAP EPS of $0.52, revenue of $10.2M beats by $4.86M

August 24, 2023 | finance.yahoo.com

CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

August 23, 2023 | benzinga.com

Preview: CollPlant Biotechnologies's Earnings

August 9, 2023 | finance.yahoo.com

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

June 26, 2023 | benzinga.com

Why CollPlant Biotechnologies Stock Is Trading Higher

May 27, 2023 | es-us.finanzas.yahoo.com

CollPlant Biotechnologies First Quarter 2023 Earnings: Beats Expectations

May 25, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Collplant Holdings (CLGN)

May 24, 2023 | msn.com

CollPlant Biotechnologies: Q1 Earnings Insights

See More Headlines

Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/24/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLGN
CUSIP: N/A
CIK: 1631487
Web: www.collplant.com
Phone: 972732325600
Fax: 972-73-232-5602
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.88
High Stock Price Target: $22.75
Low Stock Price Target: $11.00
Potential Upside/Downside: +226.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 47.00
P/E Growth: N/A
Net Income: $-16,920,000.00
Net Margins: -62.80%
Pretax Margin: -62.80%
Return on Equity: -20.61%
Return on Assets: -17.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.85
Quick Ratio: 11.28

Sales & Book Value

Annual Sales: $300,000.00
Price / Sales: 191.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.91 per share
Price / Book: 1.78

Miscellaneous

Outstanding Shares: 11,090,000
Free Float: 10,022,000
Market Cap: $57.34 million
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Yehiel Tal (Age 71)
CEO & Director
Comp: $865k
Mr. Eran Rotem CPA (Age 55)
Deputy CEO & CFO
Comp: $651k
Prof. Oded Shoseyov (Age 67)
Founder & Chief Scientist
Comp: $384k
Mr. Oren Fahimipoor (Age 41)
Vice President of Operations
Ms. Hadas Dreiher Horowitz (Age 46)
Vice President of Human Resources
Dr. Elana Gazal (Age 48)
Vice President of Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLGN Stock Analysis - Frequently Asked Questions

Should I buy or sell CollPlant Biotechnologies stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLGN shares.
View CLGN analyst ratings or view top-rated stocks.
What is CollPlant Biotechnologies' stock price target for 2024?: 2 brokerages have issued twelve-month target prices for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $22.75. On average, they expect the company's share price to reach $16.88 in the next year. This suggests a possible upside of 226.4% from the stock's current price.
View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts.
How have CLGN shares performed in 2023?: CollPlant Biotechnologies' stock was trading at $8.35 at the beginning of 2023. Since then, CLGN shares have decreased by 38.1% and is now trading at $5.17.
View the best growth stocks for 2023 here.
Are investors shorting CollPlant Biotechnologies?: CollPlant Biotechnologies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,800 shares, a decrease of 15.6% from the October 31st total of 21,100 shares. Based on an average daily trading volume, of 14,600 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the shares of the company are sold short.
View CollPlant Biotechnologies' Short Interest.
When is CollPlant Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our CLGN earnings forecast.
How were CollPlant Biotechnologies' earnings last quarter?: CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.83. The business had revenue of $10.18 million for the quarter, compared to analysts' expectations of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the firm earned ($0.39) earnings per share.

What other stocks do shareholders of CollPlant Biotechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and
When did CollPlant Biotechnologies IPO?: (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.
Who are CollPlant Biotechnologies' major shareholders?: CollPlant Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.31%), Villere ST Denis J & Co. LLC (2.71%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of CollPlant Biotechnologies?: Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLGN) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial